Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Participants
Study sponsor: Mesoblast, Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2006-04-25Actual
Enrollment · participants11Actual
Source updated2025-10-30Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.